These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

752 related articles for article (PubMed ID: 26424078)

  • 1. The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit.
    Ceccarelli G; Oliva A; d'Ettorre G; D'Abramo A; Caresta E; Barbara CS; Mascellino MT; Papoff P; Moretti C; Vullo V; Visca P; Venditti M
    BMC Infect Dis; 2015 Sep; 15():393. PubMed ID: 26424078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii.
    Bae S; Kim MC; Park SJ; Kim HS; Sung H; Kim MN; Kim SH; Lee SO; Choi SH; Woo JH; Kim YS; Chong YP
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6774-6779. PubMed ID: 27600048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and in vitro efficacy of colistin plus vancomycin and rifampin against colistin-resistant Acinetobacter baumannii causing ventilator-associated pneumonia.
    Oliva A; Cipolla A; Vullo V; Venditti M; Mastroianni CM; Falcone M
    New Microbiol; 2017 Jul; 40(3):205-207. PubMed ID: 28675246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial effects of varied combinations of meropenem, sulbactam, and colistin on a multidrug-resistant Acinetobacter baumannii isolate that caused meningitis and bacteremia.
    Lee CH; Tang YF; Su LH; Chien CC; Liu JW
    Microb Drug Resist; 2008 Sep; 14(3):233-7. PubMed ID: 18707240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii.
    Garnacho-Montero J; Amaya-Villar R; Gutiérrez-Pizarraya A; Espejo-Gutiérrez de Tena E; Artero-González ML; Corcia-Palomo Y; Bautista-Paloma J
    Chemotherapy; 2013; 59(3):225-31. PubMed ID: 24356297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.
    Park GC; Choi JA; Jang SJ; Jeong SH; Kim CM; Choi IS; Kang SH; Park G; Moon DS
    Ann Lab Med; 2016 Mar; 36(2):124-30. PubMed ID: 26709259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-Vitro Evaluation of Different Antimicrobial Combinations with and without Colistin Against Carbapenem-Resistant
    Oliva A; Garzoli S; De Angelis M; Marzuillo C; Vullo V; Mastroianni CM; Ragno R
    Molecules; 2019 Mar; 24(5):. PubMed ID: 30832412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.
    Lenhard JR; Thamlikitkul V; Silveira FP; Garonzik SM; Tao X; Forrest A; Soo Shin B; Kaye KS; Bulitta JB; Nation RL; Li J; Tsuji BT
    J Antimicrob Chemother; 2017 May; 72(5):1415-1420. PubMed ID: 28333347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii.
    Pongpech P; Amornnopparattanakul S; Panapakdee S; Fungwithaya S; Nannha P; Dhiraputra C; Leelarasamee A
    J Med Assoc Thai; 2010 Feb; 93(2):161-71. PubMed ID: 20301995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multidrug resistant Acinetobacter baumannii.
    Marie MA; Krishnappa LG; Alzahrani AJ; Mubaraki MA; Alyousef AA
    Bosn J Basic Med Sci; 2015 Oct; 15(4):24-9. PubMed ID: 26614848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo activity of vancomycin combined with colistin against multidrug-resistant strains of Acinetobacter baumannii in a Galleria mellonella model.
    Yang H; Lv N; Hu L; Liu Y; Cheng J; Ye Y; Li J
    Infect Dis (Lond); 2016; 48(3):189-94. PubMed ID: 26503239
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Soudeiha MAH; Dahdouh EA; Azar E; Sarkis DK; Daoud Z
    Front Cell Infect Microbiol; 2017; 7():209. PubMed ID: 28596943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colistin, meropenem and rifampin in a combination therapy for multi-drug-resistant Acinetobacter baumannii multifocal infection. A case report.
    Biancofiore G; Tascini C; Bisà M; Gemignani G; Bindi ML; Leonildi A; Giannotti G; Menichetti F
    Minerva Anestesiol; 2007 Mar; 73(3):181-5. PubMed ID: 17159765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of doripenem in combination with various antimicrobials against multidrug-resistant Acinetobacter baumannii: possible options for the treatment of complicated infection.
    Principe L; Capone A; Mazzarelli A; D'Arezzo S; Bordi E; Di Caro A; Petrosillo N
    Microb Drug Resist; 2013 Oct; 19(5):407-14. PubMed ID: 23659601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipopolysaccharide loss produces partial colistin dependence and collateral sensitivity to azithromycin, rifampicin and vancomycin in Acinetobacter baumannii.
    García-Quintanilla M; Carretero-Ledesma M; Moreno-Martínez P; Martín-Peña R; Pachón J; McConnell MJ
    Int J Antimicrob Agents; 2015 Dec; 46(6):696-702. PubMed ID: 26391380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic interactions between colistin and meropenem against extensively drug-resistant and pandrug-resistant Acinetobacter baumannii isolated from ICU patients.
    Vourli S; Frantzeskaki F; Meletiadis J; Stournara L; Armaganidis A; Zerva L; Dimopoulos G
    Int J Antimicrob Agents; 2015 Jun; 45(6):670-1. PubMed ID: 25795317
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates.
    Hong DJ; Kim JO; Lee H; Yoon EJ; Jeong SH; Yong D; Lee K
    Diagn Microbiol Infect Dis; 2016 Oct; 86(2):184-9. PubMed ID: 27475960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postantibiotic effect of colistin alone and combined with vancomycin or meropenem against Acinetobacter spp. with well defined resistance mechanisms.
    Bedenić B; Beader N; Godič-Torkar K; Prahin E; Mihaljević L; Ćačić M; Vraneš J
    J Chemother; 2016 Oct; 28(5):375-82. PubMed ID: 26319682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of skin and soft tissue infection due to carbapenem-resistant Acinetobacter baumannii by ampicillin-sulbactam and meropenem combination therapy.
    Hiraki Y; Yoshida M; Masuda Y; Inoue D; Tsuji Y; Kamimura H; Karube Y; Takaki K; Kawano F
    Int J Infect Dis; 2013 Dec; 17(12):e1234-6. PubMed ID: 23791858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.